t
On 12 February 2026, IXICO plc announced an amendment to a prior announcement, removing a reference to securing over £2.7 million in new revenues from two clients in the last two months. The company also announced a contract extension with an existing international pharmaceutical company for a global Phase 2 clinical trial in Huntington's Disease. This extension is worth approximately £1.5 million in additional revenues to IXICO plc over the next three years.
| Date | 12 Feb 2026 |
| Time | 08:48:45 |
| Category | Miscellaneous |
| ID | 7645S |
The following amendment has been made to the "c.£1.5 million Contract Extension" announcement released at 07:00 on 12 February 2026:
The reference in the quote to "Thanks to this contract extension IXICO has secured over £2.7m in new revenues with 2 existing clients in the last 2 months" has been removed.
IXICO plc
("IXICO", the "Company" or the "Group")
c.£1.5 million contract extension on global Phase 2 clinical trial
12 February 2026, IXICO plc (AIM: IXI) - London, UK. IXICO, a global leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug development in neurological disorders, today announced the extension of an existing contract with one of the world's leading international pharmaceutical companies following the continued progress of a Phase 2 clinical trial in Huntington's Disease.
The contract extension is worth an additional c.£1.5 million in revenues to IXICO over the next three years.
Bram Goorden, CEO of IXICO, commented: "This contract extension is an example of how IXICO's compelling IXI™ technology platform and neurological disease expertise consistently deliver gold standard outcomes for biopharma customers as they advance drug development in such a devastating neurological disease."
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 as amended by The Market Abuse (Amendment) (EU Exit) Regulations 2019. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.
Ends
For further information please contact:
|
IXICO plc |
+44 (0) 20 3763 7499 |
|
Grant Nash, Chief Financial Officer James Chandler, Chief Business Officer |
|
|
Cavendish Capital Markets Limited (Nominated Adviser and Sole Broker) |
+44 (0) 20 7220 0500 |
|
Giles Balleny, Isaac Hooper (Corporate Finance) Nigel Birks (Healthcare Specialist Sales) Harriet Ward (Corporate Broking) Michael F Johnson (Sales) |
|
About IXICO www.IXICO.com
IXICO is a global leader in neuroscience imaging and biomarker analytics, using its proprietary AI-driven platform to help advance the treatment of neurological disorders and reduce the uncertainties associated with drug discovery, development and monitoring. As a key part of the global neurological disease research community, the Company has built a global reputation and 20-year track record as an end-to-end Imaging Contract Research Organisation (iCRO) working with leading pharma companies, innovative biotech's, disease consortia and non-profit organisations. IXICO has supported hundreds of neurological clinical trials, analysed hundreds of thousands scans and built an expansive network of expert imaging centres around the world.
The IXICO Platform is tailor-made for neurological disease, reliably processing data from global trials, precisely measuring key imaging biomarkers associated with the identification, progression and treatment of diseases such as Alzheimer's, Huntington's and Parkinson's. Image data is interrogated by the Platform and IXICO's expert scientists translating complex data into clinically meaningful while minimizing data variability and increasing reproducibility.